These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26827137)

  • 21. Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.
    Lange JH; Kruse CG
    Chem Rec; 2008; 8(3):156-68. PubMed ID: 18563799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.
    Lange JH; van Stuivenberg HH; Coolen HK; Adolfs TJ; McCreary AC; Keizer HG; Wals HC; Veerman W; Borst AJ; de Looff W; Verveer PC; Kruse CG
    J Med Chem; 2005 Mar; 48(6):1823-38. PubMed ID: 15771428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain.
    Erdozain AM; Diez-Alarcia R; Meana JJ; Callado LF
    Biochem Pharmacol; 2012 Jan; 83(2):260-8. PubMed ID: 22093909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
    Silvestri C; Di Marzo V
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors.
    Horti AG; Fan H; Kuwabara H; Hilton J; Ravert HT; Holt DP; Alexander M; Kumar A; Rahmim A; Scheffel U; Wong DF; Dannals RF
    J Nucl Med; 2006 Oct; 47(10):1689-96. PubMed ID: 17015906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational design of a novel peripherally-restricted, orally active CB(1) cannabinoid antagonist containing a 2,3-diarylpyrrole motif.
    Hortala L; Rinaldi-Carmona M; Congy C; Boulu L; Sadoun F; Fabre G; Finance O; Barth F
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4573-7. PubMed ID: 20584609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripherally selective diphenyl purine antagonist of the CB1 receptor.
    Fulp A; Bortoff K; Zhang Y; Snyder R; Fennell T; Marusich JA; Wiley JL; Seltzman H; Maitra R
    J Med Chem; 2013 Oct; 56(20):8066-72. PubMed ID: 24041123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
    Seo HJ; Kim MJ; Lee SH; Lee SH; Jung ME; Kim MS; Ahn K; Kim J; Lee J
    Bioorg Med Chem; 2010 Feb; 18(3):1149-62. PubMed ID: 20045337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
    J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in CB1 cannabinoid receptor antagonists.
    Lange JH; Kruse CG
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):498-506. PubMed ID: 15338959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and structure-activity relationship of novel diarylpyrazole imide analogues as CB1 cannabinoid receptor ligands.
    Song KS; Kim MJ; Seo HJ; Lee SH; Jung ME; Kim SU; Kim J; Lee J
    Bioorg Med Chem; 2009 Apr; 17(8):3080-92. PubMed ID: 19328001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs.
    Thomas BF; Zhang Y; Brackeen M; Page KM; Mascarella SW; Seltzman HH
    AAPS J; 2006 Oct; 8(4):E665-71. PubMed ID: 17233530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel pyrazole derivatives as neutral CB₁ antagonists with significant activity towards food intake.
    Manca I; Mastinu A; Olimpieri F; Falzoi M; Sani M; Ruiu S; Loriga G; Volonterio A; Tambaro S; Bottazzi ME; Zanda M; Pinna GA; Lazzari P
    Eur J Med Chem; 2013 Apr; 62():256-69. PubMed ID: 23357307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 6-Alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds.
    Röver S; Andjelkovic M; Bénardeau A; Chaput E; Guba W; Hebeisen P; Mohr S; Nettekoven M; Obst U; Richter WF; Ullmer C; Waldmeier P; Wright MB
    J Med Chem; 2013 Dec; 56(24):9874-96. PubMed ID: 24175572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?
    Doggrell SA
    Expert Opin Investig Drugs; 2005 Mar; 14(3):339-42. PubMed ID: 15833065
    [No Abstract]   [Full Text] [Related]  

  • 36. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
    Mastinu A; Pira M; Pani L; Pinna GA; Lazzari P
    Behav Brain Res; 2012 Oct; 234(2):192-204. PubMed ID: 22771813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
    Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
    J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.
    Rinaldi-Carmona M; Barth F; Congy C; Martinez S; Oustric D; Pério A; Poncelet M; Maruani J; Arnone M; Finance O; Soubrié P; Le Fur G
    J Pharmacol Exp Ther; 2004 Sep; 310(3):905-14. PubMed ID: 15131245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists.
    Tseng SL; Hung MS; Chang CP; Song JS; Tai CL; Chiu HH; Hsieh WP; Lin Y; Chung WL; Kuo CW; Wu CH; Chu CM; Tung YS; Chao YS; Shia KS
    J Med Chem; 2008 Sep; 51(17):5397-412. PubMed ID: 18712856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).
    van Diepen H; Schlicker E; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Oct; 378(4):345-69. PubMed ID: 18654765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.